Pharmgkb Summary: Tramadol Pathway Li Gonga, Ulrike M

Total Page:16

File Type:pdf, Size:1020Kb

Pharmgkb Summary: Tramadol Pathway Li Gonga, Ulrike M View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Bern Open Repository and Information System (BORIS) 374 PharmGKB summary PharmGKB summary: tramadol pathway Li Gonga, Ulrike M. Stamerc,d, Mladen V. Tzvetkove, Russ B. Altmana,b and Teri E. Kleina Pharmacogenetics and Genomics 2014, 24:374–380 Correspondence to Teri E. Klein, PhD, Department of Genetics, Stanford University Medical Center, 318 Campus Drive, Clark Center Room S221A, MC Keywords: analgesic, CYP2D6, OCT1, opioids, OPRM1, pathway, 5448, Stanford, CA 94305, USA pharmacogenomics, pharmacokinetics, tramadol Tel: + 1 650 725 0659; fax: + 1 650 725 3863; e-mail: [email protected] a b Departments of Genetics, Bioengineering, Stanford University, Stanford, Received 14 January 2014 Accepted 5 April 2014 California, USA, cDepartment of Anaesthesiology and Pain Medicine, Inselspital, dDepartment of Clinical Research, University of Bern, Bern, Switzerland and eInstitute of Clinical Pharmacology, University Medical Center, Göttingen, Germany Background (tramadol : morphine) and 10 : 1 to 12 : 1 ratio parenterally Tramadol is a mixed centrally acting opioid analgesic [13–16]. Some patients experience inadequate pain relief used to relieve moderate to severe pain. It is commonly or adverse effects with tramadol. The main reported used alone or in combination with nonopioid analgesics, adverse drug reactions (ADRs) for tramadol are nausea, for example, paracetamol (acetaminophen) in the treat- vomiting, sweating, itching, constipation, headache, and ment for postoperative, dental, cancer, neuropathic, and central nervous system stimulation. Most of these reac- acute musculoskeletal pain [1–3]. It can also be used as tions are dose dependent. Neurotoxicity to tramadol may an adjuvant to NSAID therapy in osteoarthritis patients manifest as seizures, which have been reported in [4]. Tramadol exerts its analgesic effect through at least patients receiving tramadol both at the recommended two complementary and synergistic mechanisms: by and the high dosage ranges in animal and human stu- activating the µ-opioid receptor and inhibiting the neu- dies [17]. rotransmitter reuptake. The opioid receptor-mediated Tramadol metabolism to its major active metabolite M1 analgesic effects are mainly attributed to the active is predominantly mediated through CYP2D6 [18–20]; metabolite M1 (O-desmethyltramadol), whereas the thus, CYP2D6 plays a significant role in tramadol phar- inhibition of the neurotransmitter reuptake is caused by macokinetics and variability in drug responses [21,22]. the parent drug, thus enhancing the inhibitory effects on The influence of the CYP2D6 genotype on plasma levels pain transmission in the spinal cord [1,5,6]. Therefore, of tramadol and its metabolites as well as tramadol effi- both the parent drug and especially the M1 metabolite cacy and ADR have been reported [18,21,23–25] (see the contribute toward the overall analgesic activity of Pharmacogenomics section). This review briefly sum- tramadol. marizes the metabolism and transport of tramadol (Fig. 1) | downloaded: 13.3.2017 and discusses genetic variations affecting the pharmaco- Tramadol is administered as a racemic mixture of kinetics, efficacy, and toxicity of tramadol. Knowledge of (+ )-tramadol and (− )-tramadol enantiomers (also known genetic variants mediating the diverse pharmacological as R, R and S, S tramadol, respectively). Tramadol is a profile of tramadol may help optimize opioid therapy to synthetic opioid belonging to the class of weak opioid achieve better control of pain and less adverse effects for receptor agonists [step 2 analgesics according to the the patients. WHO ladder (http://www.who.int/cancer/palliative/painlad der/en/)]. In comparison with typical opioid agonists such as morphine at equivalent doses, tramadol shows similar Pharmacodynamics overall analgesic efficacy, and yet appears to have a lower Tramadol consists of two enantiomers [(+ )-tramadol and potential for respiratory depression or physical depen- (− )-tramadol], both of which, along with metabolite M1, dence as well as a lower incidence of constipation contribute toward overall analgesic activity by distinct [1,3,7–9]. However, cases of physical dependence and but complementary mechanisms [1,6]. In-vitro and clin- withdrawal syndrome have been reported, especially ical studies showed that the parent drug is only a weak µ- with long-term use of high tramadol doses [10–12]. The opioid receptor agonist, whereas the metabolite M1 is dose requirements for tramadol are variable and interac- significantly more potent than tramadol µ-opioid receptor tions with other drugs are common. Depending on the binding and in producing analgesia [22,26,27]. (+ )-M1 https://doi.org/10.7892/boris.69119 duration of treatment and settings, there might be certain has a significantly higher affinity for the µ-opioid receptor variance in the equipotent use of tramadol and morphine. (encoded by gene OPRM1)(Ki = 0.0034 µmol/l) than the Tramadol has been shown to be approximately equipo- parent drug (+ / − )-tramadol (Ki = 2.4 µmol/l) as well as source: tent to morphine in the range of 4 : 1 to 5 : 1 ratio orally (+ / − )-M5 (Ki = 0.1 µmol/l) and (− )-M1 (Ki = 0.24 µmol/l) 1744-6872 © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins DOI: 10.1097/FPC.0000000000000057 Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. PharmGKB summary: tramadol pathway Gong et al.375 Fig. 1 Tramadol O-desmethyl tramadol (M1) SLC22A1 Tramadol CYP3A4 CYP2D6 Liver cell CYP2B6 N-desmethyl O-desmethyl tramadol (M2) CYP3A4 tramadol (M1) CYP3A4 CYP2D6 CYP2B6 CYP2B6 UGT2B7 N,N-didesmethyl tramadol (M3) N,O-didesmethyl tramadol (M5) UGT1A8 © PharmGKB O-desmethyl N,N,O-tridesmethyl tramadol glucuronide tramadol (M4) N,O-didesmethyl tramadol conjugates N,N,O-tridesmethyl ABCC2 tramadol conjugates O-desmethyl N,N,O-tridesmethyl tramadol glucuronide tramadol conjugates N,O-didesmethyl tramadol conjugates Stylized liver cell showing candidate genes involved in the metabolism and transport of tramadol. A fully interactive version is available online at http:// www.pharmgkb.org/pathway/PA165946349. [26], suggesting that it is the compound primarily [by binding to transporter hSERT (encoded by gene responsible for opioid receptor-mediated analgesia. The SLC6A4)] and norepinephrine [by binding to transporter (+ / − )-tramadol also contribute toward analgesia by hNET (encoded by gene SLC6A2)]. The racemic tra- inhibiting reuptake of the neurotransmitters serotonin madol binds to hNET and hSERT with Ki values at 14.6 Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 376 Pharmacogenetics and Genomics 2014, Vol 24 No 7 and 1.19 µmol/l, respectively (reviewed by Raffa et al. lesser extent N,O-didesmethyltramadol (M5), are phar- [28]). Studies with the enantiomers showed that macologically active. Following bioactivation in the liver, (− )-tramadol is more potent in inhibiting norepinephrine M1 is released into the blood, enters the central nervous uptake (Ki = 1.08 µmol/l) and stimulating α-adrenergic system, and activates µ-opioid receptors. In the phase II receptors. In contrast, the (+ )-tramadol is more potent metabolism, M1 is inactivated by glucuronidation in the than (− )-tramadol for inhibiting serotonin uptake liver, mostly through UGT2B7 and UGT1A8 [35]. The (Ki = 0.87 µmol/l) and enhancing serotonin release major route of excretion for tramadol and its metabolites is [28,29]. Both enantiomers act synergistically to enhance through the kidneys, with about 30% of the dose excreted tramadol efficacy. These properties of tramadol may also in the urine as the parent drug and the rest excreted as contribute toward an increased risk of serotonin toxicity metabolites. Capillary electrophoresis assay showed that with concomitant use of serotoninergic drugs such as in healthy volunteers administered 150 mg oral tramadol, serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine, about 11.4% of the dose was excreted as (− )-tramadol, paroxetine, sertraline). SSRIs can not only inhibit tra- 16.4% as (+ )-tramadol, and 23.7% as O-desmethyl- madol metabolism by inhibiting CYP2D6 but also tramadol glucuronide in the urine [36]. This study also increase serotonin levels in the central nervous system, observed a four-fold higher excretion of (− )-O-desmethyl- an effect also mediated by tramadol. Therefore, con- tramadol glucuronide than the (+ )-O-desmethyltramadol comitant use of an SSRI and tramadol can lead to ser- glucuronide. otonin syndrome, and should be avoided [1,13,14,30]. As tramadol metabolism is primarily mediated through The FDA-approved tramadol drug label now states: ‘In CYP2D6, CYP3A4, and CYP2B6, drugs that inhibit vitro drug interaction studies in human liver microsomes CYP2D6 or induce or inhibit CYP3A4 and CYP2B6 indicates that inhibitors of CYP2D6 such as fluoxetine function should be used with caution in patients taking and its metabolite norfluoxetine, amitriptyline, and qui- tramadol because of a potential risk of drug interaction nidine inhibit the metabolism of tramadol to various [37,38]. For example, carbamazepine, a potent inducer of degrees. The full pharmacological impact of these CYP3A4, may increase tramadol metabolism through alterations in terms of either efficacy or safety is CYP3A4 to inactive metabolites and therefore reduce its unknown. Concomitant use of SEROTONIN re-uptake analgesic effect [39] (TRAMADOL
Recommended publications
  • Evidence for the Involvement of Spinal Cord 1 Adrenoceptors in Nitrous
    Anesthesiology 2002; 97:1458–65 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Evidence for the Involvement of Spinal Cord ␣ 1 Adrenoceptors in Nitrous Oxide–induced Antinociceptive Effects in Fischer Rats Ryo Orii, M.D., D.M.Sc.,* Yoko Ohashi, M.D.,* Tianzhi Guo, M.D.,† Laura E. Nelson, B.A.,‡ Toshikazu Hashimoto, M.D.,* Mervyn Maze, M.B., Ch.B.,§ Masahiko Fujinaga, M.D.ʈ Background: In a previous study, the authors found that ni- opioid peptide release in the brain stem, leading to the trous oxide (N O) exposure induces c-Fos (an immunohisto- 2 activation of the descending noradrenergic inhibitory chemical marker of neuronal activation) in spinal cord ␥-ami- nobutyric acid–mediated (GABAergic) neurons in Fischer rats. neurons, which results in modulation of the pain–noci- 1 In this study, the authors sought evidence for the involvement ceptive processing in the spinal cord. Available evi- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/6/1458/337059/0000542-200212000-00018.pdf by guest on 01 October 2021 ␣ of 1 adrenoceptors in the antinociceptive effect of N2O and in dence suggests that at the level of the spinal cord, there activation of GABAergic neurons in the spinal cord. appear to be at least two neuronal systems that are Methods: Adult male Fischer rats were injected intraperitone- involved (fig. 1). In one of the pathways, activation of ally with ␣ adrenoceptor antagonist, ␣ adrenoceptor antago- 1 2 ␣ nist, opioid receptor antagonist, or serotonin receptor antago- the 2 adrenoceptors produces either direct presynaptic nist and, 15 min later, were exposed to either air (control) or inhibition of neurotransmitter release from primary af- 75% N2O.
    [Show full text]
  • Ondansetron Does Not Attenuate the Analgesic Efficacy of Nefopam Kai-Zhi Lu 1*, Hong Shen 2*, Yan Chen 1, Min-Guang Li 1, Guo-Pin Tian 1, Jie Chen 1
    Int. J. Med. Sci. 2013, Vol. 10 1790 Ivyspring International Publisher International Journal of Medical Sciences 2013; 10(12):1790-1794. doi: 10.7150/ijms.5386 Research Paper Ondansetron Does Not Attenuate the Analgesic Efficacy of Nefopam Kai-zhi Lu 1*, Hong Shen 2*, Yan Chen 1, Min-guang Li 1, Guo-pin Tian 1, Jie Chen 1 1. Department of Anaesthesiology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China; 2. Department of Radiology, Chongqing Fifth Hospital, Chongqing.400062, China. * These authors contributed equally to this work. Corresponding author: Dr. Jie Chen: Department of Anaesthesiology, Southwest Hospital, Third Military Medical University, Gaotanyan 19 Street, Shapingba, Chongqing 400038, China. Tel: 0086-23-68754197. Fax: 0086-23-65463285. E-mail: [email protected] © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2012.10.15; Accepted: 2013.10.17; Published: 2013.10.29 Abstract Objectives: The aim of this study was to investigate if there is any interaction between ondansetron and nefopam when they are continuously co-administrated during patient-controlled intravenous analgesia (PCIA). Methods: The study was a prospective, randomized, controlled, non-inferiority clinical trial com- paring nefopam-plus-ondansetron to nefopam alone. A total of 230 postoperative patients using nefopam for PCIA, were randomly assigned either to a group receiving continuous infusion of ondansetron (Group O) or to the other group receiving the same volume of normal saline con- tinuously (Group N).
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O
    pharmaceutics Article Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling Hyeon-Cheol Jeong 1, Soo Hyeon Bae 2 , Jung-Woo Bae 3, Sooyeun Lee 3, Anhye Kim 4 , Yoojeong Jang 1 and Kwang-Hee Shin 1,* 1 College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Korea; [email protected] (H.-C.J.); [email protected] (Y.J.) 2 Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea; [email protected] 3 College of Pharmacy, Keimyung University, Daegu 42601, Korea; [email protected] (J.-W.B.); [email protected] (S.L.) 4 Department of Clinical Pharmacology and Therapeutics, CHA Bundang Medical Center, CHA University, Seongnam 13496, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-53-950-8582 Received: 6 October 2019; Accepted: 15 November 2019; Published: 17 November 2019 Abstract: Tramadol is a µ-opioid receptor agonist and a monoamine reuptake inhibitor. O-desmethyltramadol (M1), the major active metabolite of tramadol, is produced by CYP2D6. A physiologically-based pharmacokinetic model was developed to predict changes in time-concentration profiles for tramadol and M1 according to dosage and CYP2D6 genotypes in the Korean population. Parallel artificial membrane permeation assay was performed to determine tramadol permeability, and the metabolic clearance of M1 was determined using human liver microsomes. Clinical study data were used to develop the model. Other physicochemical and pharmacokinetic parameters were obtained from the literature. Simulations for plasma concentrations of tramadol and M1 (after 100 mg tramadol was administered five times at 12-h intervals) were based on a total of 1000 virtual healthy Koreans using SimCYP® simulator.
    [Show full text]
  • 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
    1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor
    [Show full text]
  • Effects of Dexfenfluramine and 5-HT3 Receptor Antagonists on Stress-Induced Reinstatement of Alcohol Seeking in Rats
    Psychopharmacology (2006) 186: 82–92 DOI 10.1007/s00213-006-0346-y ORIGINAL INVESTIGATION Anh Dzung Lê . Douglas Funk . Stephen Harding . W. Juzytsch . Paul J. Fletcher . Yavin Shaham Effects of dexfenfluramine and 5-HT3 receptor antagonists on stress-induced reinstatement of alcohol seeking in rats Received: 29 October 2005 / Accepted: 3 February 2006 / Published online: 7 March 2006 # Springer-Verlag 2006 Abstract Rationale and objectives: We previously found 0.1 mg/kg, i.p) on reinstatement induced by 10 min of that systemic injections of the 5-HT uptake blocker intermittent footshock (0.8 mA) was determined. fluoxetine attenuate intermittent footshock stress-induced Results: Systemic injections of dexfenfluramine, ondan- reinstatement of alcohol seeking in rats, while inhibition of setron or tropisetron attenuated footshock-induced rein- 5-HT neurons in the median raphe induces reinstatement statement of alcohol seeking. Injections of dexfenflur- of alcohol seeking. In this study, we further explored the amine, ondansetron, or tropisetron had no effect on role of 5-HT in footshock stress-induced reinstatement of extinguished lever responding in the absence of alcohol seeking by determining the effects of the 5-HT footshock. Conclusions: The present results provide releaser and reuptake blocker dexfenfluramine, and the 5- additional support for the hypothesis that brain 5-HT HT receptor antagonists ondansetron and tropisetron, which systems are involved in stress-induced reinstatement of decrease alcohol self-administration and anxiety-like re- alcohol seeking. The neuronal mechanisms that potentially sponses in rats, on this reinstatement. Methods: Different mediate the unexpected observation that both stimulation groups of male Wistar rats were trained to self-administer of 5-HT release and blockade of 5-HT3 receptors attenuate alcohol (12% v/v) for 28–31 days (1 h/day, 0.19 ml footshock-induced reinstatement are discussed.
    [Show full text]
  • Antidepressant Effect of the Interaction of Fluoxetine with Granisetron
    5108 EXPERIMENTAL AND THERAPEUTIC MEDICINE 18: 5108-5111, 2019 Antidepressant effect of the interaction of fluoxetine with granisetron MIHNEA COSTESCU1*, HORIA PAUNESCU1*, OANA ANDREIA COMAN1*, LAURENȚIU COMAN2* and ION FULGA1* 1Department of Pharmacology and Pharmacotherapy, Faculty of Medicine; 2Department of Physiology, Faculty of Pharmacy, UMF Carol Davila, 050474 Bucharest, Romania Received August 30, 2019; Accepted October 2, 2019 DOI: 10.3892/etm.2019.8141 Abstract. Selective serotonin reuptake inhibitors (SSRIs) may Introduction produce digestive side effects such as nausea and vomiting, diarrhoea and decreased appetite. These side effects are Some antidepressants and some antipsychotics act as antago- determined by the increase in serotonin availability at 5-HT3 nists on the 5-HT3 receptor. This receptor has binding sites receptors. Granisetron, a serotonin 5-HT3 receptor antago- for antidepressant and antipsychotic drugs, so that the 5-HT3 nist, is expected to antagonize the digestive adverse effects receptor is a therapeutic target in the treatment of depression of serotonin reuptake inhibitors, but the question is to what and psychosis as an additional mechanism to the already extent granisetron influences the antidepressant effect of these known classical ones (1). substances. The aim of this study was to determine the dose 5-HT3 receptors belong to the superfamily of receptors of fluoxetine that has an antidepressant effect in the Porsolt coupled to ion channels, structurally similar to GABA A test, and the interaction between fluoxetine and granisetron receptors, nicotinic receptors and glycine receptors. Localized with respect to the antidepressant effect in this test. In experi- in central and peripheral neurons, they generate rapid depolar- ment 1, fluoxetine was antidepressant only at 20 mg/kg body ization resulting from the opening of cationic channels (Na+, K+ weight (bw).
    [Show full text]
  • Nausea and Vomiting After Strabismus-Surgery: a Randomized Comparison of Isoflurane, Enflurane, Sevoflurane and Propofol
    The Open Clinical Trials Journal, 2009, 1, 1-6 1 Open Access Nausea and Vomiting After Strabismus-Surgery: A Randomized Comparison of Isoflurane, Enflurane, Sevoflurane and Propofol P. Kranke*,1, C.C. Apfel2, T. Papenfuss1, T. Metterlein1, F. Schuster1, R. Muellenbach1, S. Rauch1 1 and N. Roewer 1Department of Anesthesia and Critical Care, University Hospitals of Würzburg, Oberdürrbacher Str. 6, D-97080 Wuerzburg, Germany 2Perioperative Clinical Research Core, Department of Anesthesiology and Perioperative Care, University of California, San Francisco, California, USA Abstract: Background: Previous studies reported that propofol anesthesia is an effective means of preventing postoperative nausea and vomiting (PONV) after different types of surgeries. The present analysis of a large antiemetic trial is intend to compare propofol versus isoflurane, enflurane or sevoflurane with respect to the incidences of PONV after strabismus surgery. Methods: 238 ASA I - III inpatients, aged 4-65 years were randomly assigned to receive either isoflurane (group I, n = 60), enflurane (group E, n = 59), sevoflurane (group S, n = 59) or propofol (group P, n = 60) for maintenance as a subgroup of a larger trial of factorial design to investigate interventions to reduce PONV. After opioid application, patients in the inhalational groups (group I, E and S) had anesthesia induced with thiopental, those in group P received propofol for induction. Tracheal intubation was facilitated with succinylcholine. Patients were ventilated with N2O/O2 2:1. Incidence and severity of PONV as well as the need for antiemetic rescue treatment were studied during the first 24 hours after anesthesia. Paracetamol and tramadol was given to treat postoperative pain.
    [Show full text]
  • Serotonin and Thermoregulation Physiologic and Pharmacologic Aspects of Control Revealed by Intravenous M-CPP in Normal Human Subjects Paul]
    ~!''"~! f'('-'t)•V( ~1.t, .. !LSI \'ILR Serotonin and Thermoregulation Physiologic and Pharmacologic Aspects of Control Revealed by Intravenous m-CPP in Normal Human Subjects Paul]. Schwartz, M.D., Thomas A. Wehr, M.D., Norman E. Rosenthal, M.D., John]. Bartko, Ph.D., Dan A. Oren, M.D., Christopher Luetke, B.S., and Dennis L. Murphy, M. D. Mcta-c/1lorophenylpipera:i11c (111-CPP), 11 probe of crntml tlze effector mechanism primarily responsible for m-CPP­ serotonergic function, elevaft's corr /e111perat11re 111 induced core hyperthermia is increased metabolic rodents, nonhuman primates, and humans uia serotoni11 t/1cnnogenesis. Individual differences in the magnitude of receptor-mediated mechanisms. To further characterize t/1c hyperthermia were independent of m-CPP plasma the thermoregulaton1 aspects of this response, ,ue studied nmcentrations but were found to be linearly correlated 16 healthy uolunteers using multiple core and skin with the level of the previous night's core rectal temperature recording sites. Compared tu placebo, temperature minimum and mean. It appears that m-CPP intravenous 111-CPP (0. 08 mgikg) produced statisticaU11 adiuates a mode of metabolic thennogenesis governed by significant bipliasic changes in rectal lt'mperatu re, a noctu mally sensiti'ue proportional control mechanism. characterized by initial hypothermia ( - 0. ()4' Cat 1 The operation of such a proportional controller is minutes) followed by progrrssiz•e Jz11prrt/1em1ia I+ U. l-; (_ clza ractcrized by a set point and a gain, and has been at 90 minutes). 111-CPP also produced s1gnitica11t implicated in the general economy of mammalian energy increases in plasma 11urepimplz rinc I oncc11t ratio11s.
    [Show full text]
  • Salvinorin a and Related Compounds As Therapeutic Drugs for Psychostimulant-Related Disorders
    See discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/270217015 Salvinorin A and related compounds as therapeutic drugs for psychostimulant-related disorders ARTICLE in CURRENT DRUG ABUSE REVIEWS · OCTOBER 2014 DOWNLOADS VIEWS 53 322 4 AUTHORS, INCLUDING: Rafael Guimarães dos Santos João Paulo Machado-de-Sousa Ribeirão Preto Medical School, University of … University of São Paulo 35 PUBLICATIONS 114 CITATIONS 41 PUBLICATIONS 394 CITATIONS SEE PROFILE SEE PROFILE Available from: Rafael Guimarães dos Santos Retrieved on: 16 August 2015 Send Orders for Reprints to [email protected] 128 Current Drug Abuse Reviews, 2014, 7, 128-132 Salvinorin A and Related Compounds as Therapeutic Drugs for Psychostimulant-Related Disorders R.G. dos Santos*,1, J.A.S. Crippa1,2, J.P. Machado-de-Sousa1,2 and J.E.C. Hallak1,2 1Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, SP, Brazil 2National Institute for Translational Medicine (INCT-TM), CNPq, Brazil Abstract: Pharmacological treatments are available for alcohol, nicotine, and opioid dependence, and several drugs for cannabis-related disorders are currently under investigation. On the other hand, psychostimulant abuse and dependence lacks pharmacological treatment. Mesolimbic dopaminergic neurons mediate the motivation to use drugs and drug-induced euphoria, and psychostimulants (cocaine, amphetamine, and methamphetamine) produce their effects in these neurons, which may be modulated by the opioid system. Salvinorin A is a κ-opioid receptor agonist extracted from Salvia divinorum, a hallucinogenic plant used in magico-ritual contexts by Mazateca Indians in México. Salvinorin A and its analogues have demonstrated anti-addiction effects in animal models using psychostimulants by attenuating dopamine release, sensitization, and other neurochemical and behavioral alterations associated with acute and prolonged administration of these drugs.
    [Show full text]
  • Molecular Changes in Opioid Addiction: the Role of Adenylyl Cyclase and Camp/PKA System 205
    CHAPTER SEVEN Molecular Changes in Opioid Addiction: The Role of Adenylyl Cyclase and cAMP/PKA System ,1 † Patrick Chan* , Kabirullah Lutfy * Department of Pharmacy and Pharmacy Administration, Western University of Health Sciences, College of Pharmacy, Pomona, California, USA † Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, California, USA 1 Corresponding author: e-mail address: [email protected]. Contents 1. Introduction 204 2. The Adenylyl Cyclase Pathway 205 2.1 Adenylyl Cyclase 205 2.2 Protein Kinase A 207 3. Opioid Effect on cAMP-Responsive Element-Binding Protein 209 4. Molecular Changes in Brain Regions That May Underlie Opiate Dependence 211 4.1 Molecular Changes in the Locus Coeruleus 211 4.2 Molecular Changes in the Amygdala 214 4.3 Molecular Changes in the Periaqueductal Gray 216 5. Molecular Changes in the Ventral Tegmental Area 217 6. Molecular Changes in Other CNS Regions 218 7. Conclusions 219 References 219 Abstract For centuries, opiate analgesics have had a considerable presence in the treatment of moderate to severe pain. While effective in providing analgesia, opiates are notorious in exerting many undesirable adverse reactions. The receptor targets and the intra- cellular effectors of opioids have largely been identified. Furthermore, much of the mechanisms underlying the development of tolerance, dependence, and withdrawal have been delineated. Thus, there is a focus on developing novel compounds or strategies in mitigating or avoiding the development of tolerance, dependence, and withdrawal. This review focuses on the adenylyl cyclase and cyclic adenosine 3,5-monophosphate (cAMP)/protein kinase A (AC/cAMP/PKA) system as the central player in mediating the acute and chronic effects of opioids.
    [Show full text]
  • Review Article Tramadol Extended-Release for the Management of Pain Due to Osteoarthritis
    Hindawi Publishing Corporation ISRN Pain Volume 2013, Article ID 245346, 16 pages http://dx.doi.org/10.1155/2013/245346 Review Article Tramadol Extended-Release for the Management of Pain due to Osteoarthritis Chiara Angeletti, Cristiana Guetti, Antonella Paladini, and Giustino Varrassi Anesthesiology and Pain Medicine, University of L’Aquila, Viale San Salvatore, Edificio 6, Coppito, 67100 L’Aquila, Italy Correspondence should be addressed to Chiara Angeletti; [email protected] Received 11 February 2013; Accepted 29 April 2013 Academic Editors: M. I. D´ıaz-Reval, G. Krammer, and A. Ulugol Copyright © 2013 Chiara Angeletti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Current knowledge on pathogenesis of osteoarticular pain, as well as the consequent several, especially on the gastrointestinal, renal, and cardiovascular systems, side effects of NSAIDs, makes it difficult to perform an optimal management of thismixed typology of pain. This is especially observable in elderly patients, the most frequently affected by osteoarthritis (OA). Tramadol is an analgesic drug, the action of which has a twofold action. It has a weak affinity to mu opioid receptors and, at the same time, can result in inhibition of the reuptake of noradrenaline and serotonin in nociceptorial descending inhibitory control system. These two mechanisms, “opioidergic” and “nonopioidergic,” are the grounds for contrasting certain types of pain that are generally less responsive to opioids, such as neuropathic pain or mixed OA pain. The extended-release formulation of tramadol has good efficacy and tolerability and acts through a dosing schedule that allows a high level of patients compliance to therapies with a good recovery outcome for the patients’ functional status.
    [Show full text]